Sarah et al. designed active targeting nanoparticles based on the anticancer activity of lactoferrin itself and the high expression of lactoferrin receptor (LDL receptor) in breast cancer cells, and the study showed that Lactoferrin modification may enhance the targeting and internalization behavior of nanocarriers entering cancer cells (133). The gene discussed is LTF; the disease is breast cancer.